Browse articles from EyeWorld.org on the topic of the cornea. EyeWorld is the award-winning member publication of ASCRS. The magazine provides news and updates from the Society as well as clinical features in the areas of cataract, refractive, cornea, glaucoma, and practice management. It publishes quarterly with editorial direction from its medical editorial board and staff.
➤ Fast Track designation granted to one-time intravitreal gene therapy for geographic atrophy ➤ FDA clears IND for Stargardt gene therapy to move forward into a Phase 1/2 clinical trial ➤ BLA submission for retinitis pigmentosa gene therapy begins ➤ First patient dosed in Phase 1/2 trial evaluating NK therapy ➤ Enrollment complete in Phase 2b trial for PCED therapy ➤ ASCRS news and events
For about 7 years, there has been one FDA approved treatment for neurotrophic keratitis (NK): Oxervate (cenegermin-bkbj, Dompe). Before that, there was nothing. Now pharmaceutical options for NK—and persistent epithelial corneal defect (PCED) more generally—in the pipeline number about a half dozen.
Cornea Editor Julie Schallhorn, MD, gave a preview of the articles in the section and talked about the current climate for institutional funding for research.
➤ Results from second Phase 3 pivotal trial for presbyopia drop ➤ Interim Phase 2 data presented on DME, wet AMD treatment ➤ Phase 2 trial to investigate oral DME treatment ➤ First patient dosed in investigational cell therapy for photoreceptor diseases ➤ Phase 1 trial begins for minimally invasive dry AMD treatment ➤ Acquisitions and other company news ➤ ASCRS news and events
With dry eye presenting as an increasingly common issue, many companies are exploring options to treat these patients. New products in development are seeking to address different aspects of dry eye, with various amechanisms of action. Three specialists discussed some of these.
➤ FDA approves first-in-class DED drop ➤ FDA accepts NDA for topical presbyopia therapy ➤ TFOS DEWS III ➤ Topline results in Phase 3 study evaluating night driving impairment after keratorefractive surgery ➤ IND application submitted for pediatric myopia treatment ➤ Study sheds light on clinical inherited retinal diseases without genetic mutations ➤ ASCRS news and events
➤ Phase 2 results for autoimmune-related dry eye disease immunomodulator ➤ JCRS astigmatism working group publishes two papers ➤ FDA approves therapy for diabetic retinopathy ➤ Enrollment closes for largest retinal trial of its kind to date ➤ Enrollment complete for Phase 3 trial evaluating wet AMD treatment ➤ Rare Pediatric Disease Designation granted for treatment targeting several retinopathies ➤ ASCRS news and events
Three cornea specialists and one oculoplastics specialist agreed that, in some cases, closing the eyelid with either a permanent or temporary tarsorrhaphy is among the best treatments for corneal healing; the procedure is, in many ways, “the cornea’s best friend.”